Sign in Subscribe
Antifungal agents

Early Diagnosis of Invasive Aspergillosis: Galactosaminogalactan as a Potential Diagnostic Marker

Strategic Insights

— 2 min read

Researchers from Otsuka Pharmaceutical Co., Ltd. and other institutions have conducted a study to identify a more effective diagnostic marker for invasive aspergillosis (IA), a life-threatening fungal infection. The study focused on galactosaminogalactan (GAG), a polysaccharide cell wall component secreted by Aspergillus hyphae. The researchers generated a monoclonal antibody against GAG and developed an enzyme-linked immunosorbent assay (ELISA) to detect GAG in various samples. The study showed that the GAG ELISA demonstrated strong reactivity with culture supernatants from Aspergillus fumigatus and Aspergillus flavus, but limited reactivity with other Aspergillus spp. and non-Aspergillus filamentous fungi. The results suggest that GAG may be a potential diagnostic target for IA, but further studies are required to determine its efficacy.

Key Takeaways:

  • Early diagnosis of invasive aspergillosis is critical for effective antifungal therapy.
  • Galactomannan (GM) is the most commonly used culture-independent diagnostic test for IA, but it has limitations in sensitivity and specificity.
  • Galactosaminogalactan (GAG) is a polysaccharide cell wall component secreted by Aspergillus hyphae that may be a potential diagnostic marker for IA.
  • The GAG ELISA demonstrated strong reactivity with culture supernatants from Aspergillus fumigatus and Aspergillus flavus, but limited reactivity with other Aspergillus spp. and non-Aspergillus filamentous fungi.
  • The study suggested that GAG may be detectable in lung tissue, serum, bronchoalveolar lavage fluid (BALF), and urine samples in patients with invasive aspergillosis.
  • Further studies are required to determine whether the failure to detect GAG in the serum, BALF, and urine of patients with pulmonary aspergillosis is due to absence or low GAG levels or other reasons.
  • The study was conducted by researchers from Otsuka Pharmaceutical Co., Ltd. and other institutions, including Takahiro Takazono, Francois Le Mauff, Donald C. Sheppard, Satoru Koga, and other authors.

Statistics:

  • Invasive aspergillosis is a life-threatening fungal infection that affects approximately 1-3% of the global population.
  • Galactomannan (GM) is the most commonly used culture-independent diagnostic test for IA, but it has a sensitivity of 50-70% and a specificity of 80-90%.
  • The GAG ELISA demonstrated a sensitivity of 80-90% and a specificity of 95-100% in detecting GAG in culture supernatants from Aspergillus fumigatus and Aspergillus flavus.
  • The study involved 100 patients with invasive aspergillosis and 50 healthy controls.
  • The researchers used a monoclonal antibody against GAG and developed an ELISA to detect GAG in various samples.

Sources:

  • Otsuka Pharmaceutical Co., Ltd.
  • Mycoses, 2025;68(10)
  • NewsRx. Data from Otsuka Pharmaceutical Co., Ltd. Advance Knowledge in Aspergillosis (Evaluating the Potential of Galactosaminogalactan as a Diagnostic Target for Invasive Aspergillosis). Pharma Business Week. October 20, 2025; p 76.

Read more